Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

Chronic cerebrospinal venous insufficiency (CCSVI)

View commentary by Daniel Selchen, MD Following news reports last fall of a possible cure for MS, clinicians and MS Societies worldwide have been inundated with inquiries about the new procedure. Its originator, Dr. Paulo Zamboni of Ferrara, Italy, has reported that a condition that he calls chronic cerebrospinal venous insufficiency (CCSVI) is the underlying problem in multiple sclerosis. Subscribe to read more It takes 30 seconds or login using…

Consensus statement: aripiprazole for acute mania

A group in the U.K. has published a consensus statement on the use of the atypical antipsychotic aripiprazole for acute mania (Aitchison et al. J Psychopharmacol 2009; 23: 231-240). Unlike other atypical antipsychotic agents (clozapine, risperidone, olanzapine, quetiapine, ziprasidone), aripiprazole acts as a partial agonist at the dopamine D2 and serotonin 5HT-1A and 5HT-2C receptors, and as a 5HT-2A antagonist (for a recent review see Pae CU. E…

Milnacipran in major depression: meta-analysis

…Milnacipran is a dual serotonin-norepinephrine reuptake inhibitor (SNRI) in use in Europe, Asia and Australia. Its norepineprine:serotonin effects are 3:1, in contrast to other SNRIs (e.g. venlafaxine, with a 1:30 norepineprine:serotonin ratio). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

One-third of early PD patients show cognitive decline

…A longitudinal study has examined cognitive decline in 106 patients with early Parkinson’s disease (mean age 61.2 years). Cognitive decline was assessed using the Mini Mental State Examination (MMSE; mean baseline 27.8) (Kandiah et al. Mov Disord 2009); epublished February 3, 2009. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…